THE EFFECT OF PSILOCYBIN AND EUGENOL ON LIPOPOLYSACCHARIDE INDUCED INFLAMMATION IN SMALL AND LARGE INTESTINE OF MICE
Zenodo (CERN European Organization for Nuclear Research) March 1, 2026 DOI: 10.5281/zenodo.18796595 via OpenAlex
Summary
AI-generated from the abstractIntestinal inflammation arises from immune dysfunction, epithelial abnormalities, and gut microbiota imbalances, contributing to conditions like irritable bowel disease and depression. In a study using lipopolysaccharide (LPS) to induce systemic intestinal inflammation in tissue, LPS caused greater inflammation in the large intestine than in the small intestine. Psilocybin reduced inflammation in the large intestine when given either before or after LPS, but in the small intestine it worked only when given after LPS. Eugenol reduced inflammation only when applied after LPS in both tissues.
Study at a glance
| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Intestinal tissues |
| Interventions | Psilocybin Eugenol |
| Topics | Psilocybin |
| Keywords | Lipopolysaccharide Pharmacology Small intestine Mucosal inflammation |
| Key finding | Psilocybin and eugenol reduce LPS-induced inflammation more effectively in the large intestine than in the small intestine, and post-treatment is more effective than pre-treatment. |
Abstract
Intestinal inflammation is a complex gastrointestinal condition, arising from immune dysfunction, epithelial cell abnormalities, and gut microbiota imbalances. Intestinal inflammation contributes to many pathological conditions, including irritable bowel disease and depression. This study seeks to find the potential anti-inflammatory properties of psilocybin and eugenol in systemic intestinal inflammation induced by lipopolysaccharide (LPS). We evaluated the impact of these compounds on inflammatory cytokine levels in intestinal tissues in pre- and post-treatment with LPS. We found that LPS induces inflammation to a greater degree in the large intestinal tissues as compared to the small intestine. We also found that psilocybin was effective in reducing the inflammation in pre- and post-treatment in large intestine, while only effective in post-treatment in small intestine. Eugenol was only effective in reducing inflammation in post-treatment experiments in both tissues. Finally, in the large intestine, different ratios of psilocybin to eugenol (1:10, 1:20 and 1:50) were shown to be effective in reducing inflammation, while only certain ratios worked in the small intestine and were less effective. Our work demonstrates that small and large intestines respond to LPS-induced inflammation in a different manner and that psilocybin and eugenol are more efficient in reducing inflammation in the large intestine and when applied after the induction of inflammation.